Burning Rock Biotech Limited revised revenue guidance for full year of 2022. For full-year revenue growth for 2022 to be approximately 10% compared to that of 2021. This represents an upward revision compared with the CompanyÃs previous guidance on the full-year revenue growth of 5% as announced on November 15, 2022 in its financial results for the third quarter of 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.53 USD | -7.38% |
|
+9.20% | -29.78% |
1st Jan change | Capi. | |
---|---|---|
-29.78% | 66.99M | |
-16.83% | 8.62B | |
+79.26% | 4.6B | |
+16.38% | 2.98B | |
-3.15% | 2.66B | |
-4.20% | 1.98B | |
-52.37% | 1.91B | |
-13.53% | 1.56B | |
+21.59% | 1.25B | |
-47.00% | 1.08B |
- Stock Market
- Equities
- BNR Stock
- News Burning Rock Biotech Limited
- Burning Rock Biotech Limited Revises Revenue Guidance for Full Year of 2022